Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News

AML cells | image credit: TheWaterMeloonProjec - stock.adobe.com

New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+

By Kimberly Rath, PharmD

October 3rd 2024

Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.

Research graphic | Image Credit: © marikova-stock.adobe.com

Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant

By Kimberly Rath, PharmD

September 20th 2024

Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes

Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes

September 19th 2024

Risk stratification in AML could benefit from mutational scoring | image credit: faraktinov - stock.adobe.com

Mutational Score May Improve Risk Stratification of Certain Patients With AML

By AJMC Contributor

September 17th 2024

AML | Image Credit: © Dzmitry - stock.adobe.com

Key Biomarker Monitoring Improves Outcomes in ASCT Recipients With AML, MDS

By Karen Jacobson-Sive

September 9th 2024

More News

Spongy bone tissue affected by osteoporosis, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com

February 26th 2024

Methotrexate—but Not Glucocorticoids—Affects BMD in Patients With ALL

Jared Kaltwasser

The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.

Doctor holding child's hand with intravenous drip | Image Credit: © New Africa - stock.adobe.com

February 21st 2024

COVID-19–Related Chemotherapy Delays Common in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma

Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.

Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy

February 14th 2024

Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy

Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.

Vibrant abstract image of the world | Image credit: Tasnim - stock.adobe.com

February 14th 2024

Geographic, Sociodemographic Factors Significantly Influence AML in Elderly Patients

Investigators analyzed global, national, and regional trends in acute myeloid leukemia (AML), which predominantly affects individuals aged 60 to 89 years.

Lonely sad girl hugging a soft teddy bear | Image credit: Pictures Paradise - stock.adobe.com

February 8th 2024

Research Indicates In Utero Origins of Acute Leukemia in Children

Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.

Man holding AML word on wooden cube | Image Credit: Andrey-stock.adobe.com

January 31st 2024

In AML, Immunotherapy Shows Promise to Expand Treatment Toolbox

Jared Kaltwasser

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).

AML Acute Myeloid Leukemia | Image Credit: momius-stock.adobe.com

January 29th 2024

ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML

Jared Kaltwasser

The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.

Blood cells flowing - Катерина Євтехова - stock.adobe.com

January 27th 2024

Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS

The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.

ASH 2023: Coverage of ALL

January 20th 2024

ASH 2023: Coverage of ALL

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib

January 5th 2024

Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib

Red Blood Cells - Design Cells stock.adobe.com

December 22nd 2023

alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com

December 8th 2023

Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Child laying in hospital bed | Image credit: wavebreak3 - stock.adobe.com.jpg

November 3rd 2023

High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds

A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

October 13th 2023

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

Blood cells | Image credit: flashmovie - stock.adobe.com

September 8th 2023

AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements

A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.

image of leukemia cell

August 29th 2023

Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds

A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions